HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xiang, A. H. Articles by Buchanan, T. A. Search for Related Content PubMed PubMed Citation Articles by Xiang, A. H. Articles by Buchanan, T. A. Social Bookmarking                What's this?

Effect of Pioglitazone on Pancreatic ß-Cell Function and Diabetes Risk in Hispanic Women With Prior Gestational Diabetes

¹ Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
² Department of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, California
³ Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California

Address correspondence and reprint requests to Thomas A. Buchanan, MD, Room 6602 GNH, 1200 N. State St., Los Angeles CA, 90033. E-mail: buchanan{at}usc.edu

Key Words: AIR, acute insulin response • DI, disposition index • IVGTT, intravenous glucose tolerance test • OGTT, oral glucose tolerance test • PIPOD, Pioglitazone In Prevention Of Diabetes • TRIPOD, Troglitazone In Prevention Of Diabetes

The Pioglitazone In Prevention Of Diabetes (PIPOD) study was conducted to evaluate ß-cell function, insulin resistance, and the incidence of diabetes during treatment with pioglitazone in Hispanic women with prior gestational diabetes who had completed participation in the Troglitazone In Prevention Of Diabetes (TRIPOD) study. Women who completed the TRIPOD study were offered participation in the PIPOD study for a planned 3 years of drug treatment and 6 months of postdrug washout. Oral glucose tolerance tests were performed annually on pioglitazone and at the end of the postdrug washout. Intravenous glucose tolerance tests (IVGTTs) for assessment of insulin sensitivity and ß-cell function were conducted at baseline, after 1 year on pioglitazone, and at the end of the postdrug washout. Of 95 women who were not diabetic at the end of the TRIPOD study, 89 enrolled in the PIPOD study, 86 completed at least one follow-up visit, and 65 completed all study visits, including the postdrug tests. Comparison of changes in ß-cell compensation for insulin resistance across the TRIPOD and PIPOD studies revealed that pioglitazone stopped the decline in ß-cell function that occurred during placebo treatment in the TRIPOD study and maintained the stability of ß-cell function that had occurred during troglitazone treatment in the TRIPOD study. The risk of diabetes, which occurred at an average rate of 4.6% per year, was lowest in women with the largest reduction in total IVGTT insulin area after 1 year of treatment. The similarity of findings between the PIPOD and TRIPOD studies support a class effect of thiazolidinedione drugs to enhance insulin sensitivity, reduce insulin secretory demands, and preserve pancreatic ß-cell function, all in association with a relatively low rate of type 2 diabetes, in Hispanic women with prior gestational diabetes.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. A. Buchanan, A. Xiang, S. L. Kjos, and R. Watanabe What Is Gestational Diabetes? Diabetes Care, July 1, 2007; 30(Supplement_2): S105 - S111. [Full Text] [PDF]

				J. L. Kitzmiller, L. Dang-Kilduff, and M. M. Taslimi Gestational Diabetes After Delivery: Short-term management and long-term risks Diabetes Care, July 1, 2007; 30(Supplement_2): S225 - S235. [Full Text] [PDF]

				R. E. Ratner Prevention of Type 2 Diabetes in Women With Previous Gestational Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S242 - S245. [Full Text] [PDF]

				T. A. Buchanan (How) Can We Prevent Type 2 Diabetes? Diabetes, June 1, 2007; 56(6): 1502 - 1507. [Full Text] [PDF]

				K. Cusi, S. Kashyap, A. Gastaldelli, M. Bajaj, and E. Cersosimo Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1775 - E1781. [Abstract] [Full Text] [PDF]

				C. Kim, D. K. Berger, and S. Chamany Recurrence of Gestational Diabetes Mellitus: A systematic review Diabetes Care, May 1, 2007; 30(5): 1314 - 1319. [Abstract] [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				E. Tozzo, R. Ponticiello, J. Swartz, D. Farrelly, R. Zebo, G. Welzel, D. Egan, L. Kunselman, A. Peters, L. Gu, et al. The Dual Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 107 - 115. [Abstract] [Full Text] [PDF]

				M. J. Franz The Evidence Is In: Lifestyle Interventions Can Prevent Diabetes American Journal of Lifestyle Medicine, March 1, 2007; 1(2): 113 - 121. [Abstract] [PDF]

				A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883. [Abstract] [Full Text] [PDF]

				J. A. Moibi, D. Gupta, T. L. Jetton, M. Peshavaria, R. Desai, and J. L. Leahy Peroxisome Proliferator-Activated Receptor-{gamma} Regulates Expression of PDX-1 and NKX6.1 in INS-1 Cells Diabetes, January 1, 2007; 56(1): 88 - 95. [Abstract] [Full Text] [PDF]

				L. E. John, M. P. Kane, R. S. Busch, and R. A. Hamilton Expanded Use of Exenatide in the Management of Type 2 Diabetes Diabetes Spectr, January 1, 2007; 20(1): 59 - 63. [Full Text] [PDF]

				N. Rasouli, P. A Kern, E. A. Reece, and S. C. Elbein Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E359 - E365. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Diabetes Prevention DOC News, November 1, 2006; 3(11): 3 - 19. [Full Text]